Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1956 1
1959 1
1960 2
1961 5
1962 1
1963 5
1964 5
1965 5
1966 2
1967 5
1968 4
1969 2
1970 8
1971 2
1972 2
1973 6
1974 5
1975 6
1976 10
1977 9
1978 5
1979 7
1980 11
1981 13
1982 6
1983 12
1984 13
1985 16
1986 17
1987 7
1988 15
1989 8
1990 6
1991 8
1992 11
1993 13
1994 15
1995 14
1996 24
1997 13
1998 27
1999 26
2000 28
2001 20
2002 14
2003 20
2004 21
2005 22
2006 26
2007 40
2008 30
2009 37
2010 39
2011 37
2012 53
2013 51
2014 55
2015 61
2016 68
2017 76
2018 77
2019 99
2020 103
2021 113
2022 97
2023 81
2024 93
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,538 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Reck M, et al. Among authors: hotta k. N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8. N Engl J Med. 2016. PMID: 27718847 Free article. Clinical Trial.
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Paz-Ares L, et al. Among authors: hotta k. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. Lancet. 2019. PMID: 31590988 Clinical Trial.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Among authors: hotta k. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Musso E, Havel L, Bondarenko I, Losonczy G, Conev N, Mann H, Dalvi TB, Jiang H, Goldman JW. Paz-Ares L, et al. Among authors: hotta k. ESMO Open. 2022 Apr;7(2):100408. doi: 10.1016/j.esmoop.2022.100408. Epub 2022 Mar 10. ESMO Open. 2022. PMID: 35279527 Free PMC article. Clinical Trial.
Echinomycin biosynthesis.
Sato M, Nakazawa T, Tsunematsu Y, Hotta K, Watanabe K. Sato M, et al. Among authors: hotta k. Curr Opin Chem Biol. 2013 Aug;17(4):537-45. doi: 10.1016/j.cbpa.2013.06.022. Epub 2013 Jul 12. Curr Opin Chem Biol. 2013. PMID: 23856054 Review.
Colonoscopy screening and surveillance guidelines.
Saito Y, Oka S, Kawamura T, Shimoda R, Sekiguchi M, Tamai N, Hotta K, Matsuda T, Misawa M, Tanaka S, Iriguchi Y, Nozaki R, Yamamoto H, Yoshida M, Fujimoto K, Inoue H. Saito Y, et al. Among authors: hotta k. Dig Endosc. 2021 May;33(4):486-519. doi: 10.1111/den.13972. Dig Endosc. 2021. PMID: 33713493 Review.
Post-polypectomy surveillance: the present and the future.
Sekiguchi M, Matsuda T, Hotta K, Saito Y. Sekiguchi M, et al. Among authors: hotta k. Clin Endosc. 2022 Jul;55(4):489-495. doi: 10.5946/ce.2022.097. Epub 2022 Jul 11. Clin Endosc. 2022. PMID: 35811404 Free PMC article. Review.
Transient mixed chimerism for allograft tolerance.
Oura T, Hotta K, Cosimi AB, Kawai T. Oura T, et al. Among authors: hotta k. Chimerism. 2015 Apr 3;6(1-2):21-6. doi: 10.1080/19381956.2015.1111975. Epub 2015 Oct 30. Chimerism. 2015. PMID: 26517761 Free PMC article. Review.
1,538 results